The effectiveness of currently existing immune checkpoint inhibitors for treating KRAS mutation-containing pancreatic cancer is disappointing and indicates the need to explore additional pathways involved in immune evasion that should be targeted for therapy. Here, KRAS is linked to pancreatic neoplasm.